Impact of Insulin Degludec in Hospitalized Patients With and Without Type 2 Diabetes Requiring Parenteral/Enteral Nutrition: An Observational Study.

Advances in Therapy
Giuseppe FatatiMariangela Palazzi

Abstract

Hyperglycemia in inpatients is a major problem, especially when nutritional support is required. This study aims to assess the impact of treatment with insulin degludec (IDeg) on mean blood glucose (BG) and glycemic variability in noncritical hospitalized patients with and without type 2 diabetes (T2DM) receiving enteral and/or parenteral nutrition (EN, PN). Mean BG and glycemic variability from admission up to 7 days of hospitalization were evaluated in consecutive cases with and without T2DM. Percentage of coefficient of variation (CV) for glucose was used to express glycemic variability. Overall, 26 patients (13 with and 13 without T2DM) were admitted to the hospital for any cause. Subjects were 65.4% men and they were mainly elderly (mean age 66.3 ± 13.4 years). PN was administered in 88.5% of patients and EN in 19.2%. At admission, mean HbA1c level was 5.9 ± 0.7% in patients without diabetes and 9.1 ± 2.5% in patients with T2DM. During hospitalization, mean daily BG levels changed from 151 ± 47.3 mg/dl (day 1) to 157 ± 66.7 mg/dl (day 7) in patients without diabetes and from 210 ± 66.5 mg/dl to 192 ± 48.6 mg/dl in patients with T2DM. CV decreased from 14% (day 1) to 11% (day 7) in patients without diabetes and from 20% (da...Continue Reading

References

Feb 24, 2001·Critical Care Clinics·K C McCowenB R Bistrian
Oct 11, 2005·Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition·Karen C McCowen, Bruce R Bistrian
Oct 28, 2008·Diabetes Research and Clinical Practice·Antonio CerielloDario Giugliano
May 26, 2009·Lancet·Kathleen M DunganJean-Charles Preiser
Sep 20, 2011·Best Practice & Research. Clinical Endocrinology & Metabolism·Farnoosh FarrokhiGuillermo E Umpierrez
Oct 15, 2011·Current Diabetes Reports·Aidar R Gosmanov, Guillermo E Umpierrez
Jan 10, 2012·The Journal of Clinical Endocrinology and Metabolism·Guillermo E UmpierrezUNKNOWN Endocrine Society
Oct 16, 2012·Current Diabetes Reports·Aidar R Gosmanov, Guillermo E Umpierrez
Apr 25, 2013·Diabetes·F John Service
Aug 21, 2013·Indian Journal of Endocrinology and Metabolism·Surabhi Venkata Satya KrishnaKirtikumar D Modi
Oct 17, 2013·Diabetes Research and Clinical Practice·Simona FrontoniAntonio Ceriello
May 13, 2015·Diabetes Research and Clinical Practice·Jiten VoraLuigi Meneghini
Aug 25, 2015·Diabetes & Metabolism Journal·Sunghwan Suh, Jae Hyeon Kim
Jun 7, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Natalino SimioniVera Frison
Jun 13, 2017·The New England Journal of Medicine·Steven P MarsoUNKNOWN DEVOTE Study Group
Dec 10, 2017·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Citations

Oct 2, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Sherwin C D'Souza, Davida F Kruger
Oct 26, 2021·Current Medical Research and Opinion·Abraham Edgar Gracia-RamosFrancisco Javier Carrasco-Sánchez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.